Three Or More Ring Hetero Atoms In The Six-membered Hetero Ring Patents (Class 514/222.5)
  • Patent number: 6630464
    Abstract: Certain derivatives of acridones and benzothiadiazines have been found to have anti-cancer properties by virtue of their specific inhibition of the cyclin D dependant kinase CDK4. These molecules inhibit CDK4 activity more than they inhibit the activity of other such kinases (e.g. CDC2 and CDK2). This specificity results in an improved therapeutic index when used as drugs to treat susceptible cancers.
    Type: Grant
    Filed: February 18, 2000
    Date of Patent: October 7, 2003
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Michael J. Kelley, Kazuhiko Nakagawa, Barry Roy Dent
  • Patent number: 6608051
    Abstract: A blood collection system and method are disclosed in which taurolidine, a neutralizing agent for pathogens is added to the blood collected in standard blood bags. The taurolidine agent may be prepositioned in the collection bag prior to the collection of blood or alternatively the taurolidine may be added after the collection of blood has been completed.
    Type: Grant
    Filed: March 10, 2000
    Date of Patent: August 19, 2003
    Assignee: MedPointe Healthcare Inc.
    Inventor: James C. Costin
  • Publication number: 20030139397
    Abstract: Compounds of Formula (I), and their N-oxides and agriculturally suitable salts, are disclosed which are useful as arthropodicides wherein A is H; E is H or C1-C3 alkyl; or A and E can be taken together to form —CH2—, —CH2CH2—, —O—, —S—, —S(O)—, —S(O)2—, —NR8—, —OCH2—, —SCH2—, —N(R8)CH2—, substituted —CH2— and substituted —CH2CH2—, the substituents independently selected from 1-2 halogen and 1-2 methyl; W is N or CR4;X is CR5R6, O, S, NR7 or a direct bond, provided that when W is N, then X is other than a direct bond; Y is H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C3 alkylsulfonyl, C3-C6 cycloalkyl, C3-C6 cycloalkylalkyl, NR9R10, N═CR11R12, OR7, COR13, CO2R14 or C1-C6 alkyl substituted by at least one group selected from halogen, C1-C3 alkoxy, CN, NO2, S(O)1R15, COR13, CO2R14 and optionally substituted phenyl; Z is O or S; and R2, R3, R4, R5, R6, R7, R8, R9
    Type: Application
    Filed: August 28, 2002
    Publication date: July 24, 2003
    Inventor: David Walter Piotrowski
  • Publication number: 20030100551
    Abstract: The invention provides a method of inhibiting tumor growth in a mammal, by administering to the mammal composition containing taurolidine, taurultam, or a biologically active derivative thereof. The composition is administered to directly contact a tumor cell at a dose sufficient to induce cell death by apoptosis.
    Type: Application
    Filed: August 5, 2002
    Publication date: May 29, 2003
    Inventors: Paul Calabresi, James Darnowski
  • Patent number: 6569852
    Abstract: The present invention relates to a method of inhibiting or preventing infection and blood coagulation in or near a medical prosthetic device after the device has been inserted in a patient by administering to the device a pharmaceutically effective amount of a composition having: (A) at least one taurinamide derivative, and (B) at least one compound selected from the group consisting of biologically acceptable acids and biologically acceptable salts thereof, whereby there are no systemic anti-clotting and no systemic biocidal effects.
    Type: Grant
    Filed: April 19, 2000
    Date of Patent: May 27, 2003
    Assignee: Biolink Corporation
    Inventor: Klaus Sodemann
  • Publication number: 20030092707
    Abstract: A method of treating a patient with breast cancer includes administering to the patient a breast cancer cell proliferation-inhibiting amount of a methylol-containing compound such as taurolidine, taurultam or a mixture thereof.
    Type: Application
    Filed: October 15, 2002
    Publication date: May 15, 2003
    Inventors: H. Paul Redmond, Rolf W. Pfirrmann
  • Patent number: 6562811
    Abstract: Pyridine compounds of general formula: wherein —R1 represents in which R11 is hydrogen, C1-6 alkyl, halogen, hydroxy, C1-12 alkoxy, nitro, amino, C1-6 alkylsulfonylamino, C1-6 alkoxycarbonyl, C1-6 alkylamino, di(C1-6 alkyl)amino, C1-6 alkanoylamino, phenyl C1-6 alkylamino, phenylsulfonylamino, or —O—(CH2)n—R111; R2 represents hydrogen or halogen; R3 represents hydrogen, —CR31R32R33, or —NR34R35; R4 is hydrogen, carbamoyl, CN, carboxyl, etc.; R5 is amino, C1-6 alkylamino, di C1-6 alkylamino, etc. or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity.
    Type: Grant
    Filed: September 18, 2001
    Date of Patent: May 13, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Toshiki Murata, Masaomi Umeda, Sachiko Sakakibara, Takashi Yoshino, Hiroki Sato, Tsutomu Masuda, Yuji Koriyama, Mitsuyuki Shimada, Takuya Shintani, Hiroshi Kadono, Timothy B. Lowinger, Karl B. Ziegelbauer, Kinji Fuchikami, Hiroshi Komura
  • Patent number: 6555534
    Abstract: The use of 4,4-methylenebis (tetrahydro-1,2-4-thiadiazine-1,1 -dioxide) in the eradication and control of the microorganism Helicobacter pylori in humans is disclosed.
    Type: Grant
    Filed: March 10, 1999
    Date of Patent: April 29, 2003
    Assignee: Medpointe Healthcare Inc.
    Inventor: James C. Costin
  • Publication number: 20030078257
    Abstract: The invention provides a method of inhibiting tumor growth in a mammal, by administering to the mammal composition containing taurolidine, taurultam, or a biologically active derivative thereof. The composition is administered to directly contact a tumor cell at a dose sufficient to induce cell death by apoptosis.
    Type: Application
    Filed: November 21, 2002
    Publication date: April 24, 2003
    Inventors: Paul Calabresi, James Darnowski
  • Publication number: 20030069229
    Abstract: The invention relates to methods for preventing and treating disseminating cancers. Inhibition metastases of a primary tumor to a liver tissue is carried out by directly contacting a liver tissue with Taurolidine.
    Type: Application
    Filed: October 1, 2002
    Publication date: April 10, 2003
    Inventors: Jack R. Wands, Rolf I. Carlson, Paul Maggio
  • Publication number: 20030064980
    Abstract: Compound represented by the structural formula 1
    Type: Application
    Filed: June 6, 2002
    Publication date: April 3, 2003
    Inventors: Neng-Yang Shih, Ho-Jane Shue, Gregory A. Reichard, Sunil Paliwal, David J. Blythin, John J. Piwinski, Dong Xiao, Xiao Chen
  • Patent number: 6521616
    Abstract: The invention provides a method of inhibiting tumor growth in a mammal, by administering to the mammal composition containing taurolidine, taurultam, or a biologically active derivative thereof. The composition is administered to directly contact a tumor cell at a dose sufficient to induce cell death by apoptosis.
    Type: Grant
    Filed: December 6, 2000
    Date of Patent: February 18, 2003
    Assignee: Rhode Island Hospital, A Lifespan Partner
    Inventors: Paul Calabresi, James Darnowski
  • Publication number: 20030008865
    Abstract: Complex compounds or adducts of xanthine derivatives, for example propentofylline or pentoxyfylline, or phenazone derivatives, for example phenazone, propylphenazone and aminophenazone, and acesulfame-H, in which the components are present in a molar ratio of 1:1 or 1:2, have a pleasantly sweet taste and are suitable for numerous applications, for example in pharmaceuticals. The compounds can be prepared from the dissolved components by simple reaction.
    Type: Application
    Filed: June 7, 2002
    Publication date: January 9, 2003
    Inventor: Andreas Burgard
  • Patent number: 6500818
    Abstract: Compounds having the following formula wherein L, M, R2, R3, R4, R5, R6, R7, X1 and X2 are as defined in the specification, pharmaceutically-acceptable salt thereof, useful for treating depression, anxiety, asthma, rheumatoid arthritis, Alzheimer's disease, cancer, schizophrenia, oedema, allergic rhinitis, inflammation, pain, gastrointestinal-hypermotility, emesis, Huntington's disease, psychoses, hypertension, migraine, bladder hypermotility, or urticaria, compositions including such compounds and processes for making such compounds.
    Type: Grant
    Filed: March 30, 2001
    Date of Patent: December 31, 2002
    Assignee: Astrazeneca AB
    Inventors: Peter Robert Bernstein, Robert Frank Dedinas, Cyrus John Ohnmacht, Keith Russell
  • Patent number: 6498157
    Abstract: The present invention relates to a method of inhibiting or preventing infection and blood coagulation in or near a medical prosthetic device after said device has been inserted in a patient comprising administering to the device a pharmaceutically effective amount of a composition comprising: (A) at least one taurinamide derivative, and (B) at least one compound selected from the group consisting of biologically acceptable acids and biologically acceptable salts thereof, whereby there are no systemic anti-clotting and no systemic biocidal effects.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: December 24, 2002
    Assignee: Biolink Corporation
    Inventor: Klaus Sodemann
  • Patent number: 6495546
    Abstract: Propanolamine derivatives represented by the following formula (I): These derivatives may be &bgr;3 agonists and exert sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic and anti-urinary incontinence and anti-pollakiuria activities. Pharmaceutical compositions containing such propanolamine derivatives, methods for the prevention and/or treatment diseases using these propanolamine derivatives, and processes for their preparation are also described.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: December 17, 2002
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Kiyoshi Taniguchi, Minoru Sakurai, Naoaki Fujii, Kumi Hosoi, Yasuyo Tomishima, Hisashi Takasugi, Hajime Sogabe, Hirofumi Ishikawa, Naomi Hanioka
  • Patent number: 6479481
    Abstract: Methods and compositions for the treatment and/or prophylaxis and/or suppression of primary and/or secondary tumors of the central nervous system (brain and spinal cord, eyes) in mammalian subjects are disclosed, wherein an effective dose of a methylol transfer agent such as Taurolidine and/or Taurultam and/or a bioequivalent is administered to a mammalian subject suffering from, or at risk of growth of, tumors of the central nervous system. Furthermore, methods for local application of Taurolidine and/or Taurultam and/or a bioequivalent in solution are disclosed using microdialysis methods, irrigation methods, implantation methods and angiographic methods.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: November 12, 2002
    Assignee: Ed. Geistlich Soehne AG fur Chemische Industrie
    Inventors: Ruediger Stendel, Rolf W. Pfirrmann
  • Publication number: 20020161003
    Abstract: The use of 4,4-methylenebis (tetrahydro-1,2,4-thiadiazine-1,2-dioxide) in the prevention and control of the development of antibiotic drug resistance in staphylococcus aureus bacteria and in the prevention of bacteria-to-bacteria transfer of genes capable of resisting antibiotics is disclosed.
    Type: Application
    Filed: July 25, 2001
    Publication date: October 31, 2002
    Inventor: James C. Costin
  • Patent number: 6461646
    Abstract: The invention provides a pharmaceutical composition for preventing and/or curing digestive disorders such as digestive ulcers, gastritis, etc. The pharmaceutical composition contains, as the active ingredient, an aluminosilicate having silver and zinc ions, and it has an excellent effect for protecting gastric mucous membrane and an excellent effect of promoting the curing of a gastric ulcer.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: October 8, 2002
    Assignees: Lintec Corporation, Sinanen Zeomic Co., Ltd.
    Inventor: Mikio Ito
  • Publication number: 20020123491
    Abstract: Compound represented by the structural formula 1
    Type: Application
    Filed: December 14, 2000
    Publication date: September 5, 2002
    Inventors: Neng-Yang Shih, Ho-Jane Shue, Gregory A. Reichard, Sunil Paliwal, David J. Blythin, John J. Piwinski, Dong Xiao, Xiao Chen
  • Publication number: 20020119968
    Abstract: The invention concerns compounds of formula (I) 1
    Type: Application
    Filed: March 8, 2001
    Publication date: August 29, 2002
    Applicant: ZENECA LIMITED
    Inventors: Alan Wellington Faull, Andrew Stocker, Colette Marie Mayo, John Preston
  • Patent number: 6436926
    Abstract: Compositions comprising 4,4′-methylenebis(tetrahydro-1,2,4-thiadiazine) 1,1,1′,1′,-tetraoxide and their use in treating dermatologic disorders are disclosed.
    Type: Grant
    Filed: September 4, 2001
    Date of Patent: August 20, 2002
    Assignee: MedPointe, Inc.
    Inventor: James C. Costin
  • Publication number: 20020111328
    Abstract: Tumor growth and metastases in cancer patients are inhibited by administration of a combination therapy including effective amounts of 5-Fluorouracil and a methylol transfer agent such as taurolidine, taurultam or mixtures thereof.
    Type: Application
    Filed: November 27, 2001
    Publication date: August 15, 2002
    Inventors: H. Paul Redmond, Rolf W. Pfirrmann
  • Publication number: 20020111346
    Abstract: The present invention relates to a method of inhibiting or preventing infection and blood coagulation in or near a medical prosthetic device after said device has been inserted in a patient comprising administering to the device a pharmaceutically effective amount of a composition comprising:
    Type: Application
    Filed: November 30, 2001
    Publication date: August 15, 2002
    Applicant: Biolink Corporation
    Inventor: Klaus Sodemann
  • Publication number: 20020103187
    Abstract: Compositions comprising 4,4′-methylenebis(tetrahydro-1,2,4-thiadiazine) 1,1,1′,1′,-tetraoxide and their use in treating dermatologic disorders are disclosed.
    Type: Application
    Filed: September 4, 2001
    Publication date: August 1, 2002
    Inventor: James C. Costin
  • Publication number: 20020098164
    Abstract: Tumor metastases in cancer patients are inhibited by administration of a combination therapy including effective amounts of Interleukin-2 and a methylol transfer agent such as taurolidine, taurultam or mixtures thereof.
    Type: Application
    Filed: October 23, 2001
    Publication date: July 25, 2002
    Inventors: H. Paul Redmond, Rolf W. Pfirrmann
  • Patent number: 6423706
    Abstract: The present invention relates to a method of inhibiting or preventing infection and blood coagulation in or near a medical prosthetic device after said device has been inserted in a patient comprising administering to the device a pharmaceutically effective amount of a composition comprising: (A) at least one taurinamide derivative, and (B) at least one compound selected from the group consisting of biologically acceptable acids and biologically acceptable salts thereof, whereby there are no systemic anti-clotting and no systemic biocidal effects.
    Type: Grant
    Filed: December 20, 2000
    Date of Patent: July 23, 2002
    Assignee: Biolink Corporation
    Inventor: Klaus Sodemann
  • Patent number: 6423718
    Abstract: The present invention relates to 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones of formula I: or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
    Type: Grant
    Filed: August 2, 2000
    Date of Patent: July 23, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Jeffrey W. Corbett, Soo S. Ko
  • Publication number: 20020091123
    Abstract: Taurolidine and/or taurultam is administered during and after surgical removal of a cancerous tumor to treat abdominal cancer.
    Type: Application
    Filed: October 9, 2001
    Publication date: July 11, 2002
    Inventors: H. Paul Redmond, Rolf W. Pfirrmann
  • Patent number: 6407097
    Abstract: The invention relates to novel methoximinomethyloxathiazines, to two processes for their preparation and to their use as pesticides.
    Type: Grant
    Filed: October 30, 2000
    Date of Patent: June 18, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventors: Herbert Gayer, Peter Gerdes, Ulrich Heinemann, Bernd-Wieland Krüger, Klaus Stenzel
  • Patent number: 6407098
    Abstract: The application relates to novel heterocycloalkenes, to a number of processes for their preparation and to their use as fungicide.
    Type: Grant
    Filed: October 31, 2000
    Date of Patent: June 18, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventors: Bernd-Wieland Krüger, Ulrich Heinemann, Herbert Gayer, Lutz Assmann, Ralf Tiemann, Thomas Seitz, Gerd Hänssler, Klaus Stenzel, Stefan Dutzmann
  • Patent number: 6384056
    Abstract: This invention relates to pharmaceutical compositions and methods for treating a vision disorder, improving vision, treating memory impairment, or enhancing memory performance using heterocyclic thioesters and ketones.
    Type: Grant
    Filed: August 14, 1998
    Date of Patent: May 7, 2002
    Assignee: GPI NIL Holdings, Inc.
    Inventors: Douglas T. Ross, Hansjörg Sauer, Gregory S. Hamilton, Joseph P. Steiner
  • Publication number: 20020052366
    Abstract: The invention provides a method of inhibiting tumor growth in a mammal, by administering to the mammal composition containing taurolidine, taurultam, or a biologically active derivative thereof. The composition is administered to directly contact a tumor cell at a dose sufficient to induce cell death by apoptosis.
    Type: Application
    Filed: December 6, 2000
    Publication date: May 2, 2002
    Inventors: Paul Calabresi, James Darnowski
  • Publication number: 20020049200
    Abstract: The invention provides a method of inhibiting tumor growth in a mammal, by administering to the mammal composition containing methylol-containing compound. The composition is administered to directly contact a tumor cell at a dose sufficient to induce cell death by apoptosis.
    Type: Application
    Filed: December 6, 2000
    Publication date: April 25, 2002
    Inventors: Paul Calabresi, James Darnowski, James Costin
  • Patent number: 6362134
    Abstract: Compounds of formula (I), in which R1, R2 and R3 are as defined in claim 1, are particularly suitable as herbicides.
    Type: Grant
    Filed: July 1, 1998
    Date of Patent: March 26, 2002
    Assignee: Syngenta Investment Corporation
    Inventors: Helmut Zondler, André Stoller
  • Patent number: 6350251
    Abstract: Disclosed herein is an internal prosthetic device comprising: (a) device for providing a continuous flowpath, crossing a patient's skin, between an external-to-patient site and an internal-to-patient site; (b) means for blocking the flowpath; and (c) a biocidal lock including: (i) an anticoagulant; and (ii) a non-antibiotic biocide.
    Type: Grant
    Filed: January 18, 2000
    Date of Patent: February 26, 2002
    Assignee: Biolink Corporation
    Inventors: Frank R. Prosl, Brian K. Estabrook, Klaus Sodemann
  • Publication number: 20020004502
    Abstract: Patients suffering from inflammatory bowel disease such as Crohn's disease or ulcerative colitis are treated either orally or intravenously with methylol transfer agents, such as taurolidine and/or taurultam. These agents can be used in combination with other drugs thereby allowing the use of smaller amounts of the other drugs and limiting unwanted side effects.
    Type: Application
    Filed: January 4, 2001
    Publication date: January 10, 2002
    Inventors: H. Paul Redmond, Rolf W. Pfirrmann
  • Patent number: 6337340
    Abstract: This invention relates to novel compositions and uses of carboxylic acid or isostere of a heterocyclic ring compound having two or more heteroatoms within the heterocyclic ring and wherein the heterocyclic ring has at least one substituent attached thereto, the substituent selected from the group consisting of a diketo, a sulfonamide, a urea, a carbamate, and substituted derivatives thereof for treating a vision disorder or improving vision or treating memory impairment or enhancing memory performance in an animal.
    Type: Grant
    Filed: August 14, 1998
    Date of Patent: January 8, 2002
    Assignee: GPI NIL Holdings, Inc.
    Inventors: Douglas T. Ross, Hansjörg Sauer, Gregory S. Hamilton, Joseph P. Steiner
  • Patent number: 6326368
    Abstract: The present invention provides novel compounds, and pharmaceutical compositions thereof, and methods of using same in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsey, irritable bowl syndrome, immune supression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, drug and alcohol withdrawal symptoms, drug addiction, inflammatory disorders, or fertility problems. The novel compounds provided by this invention are those of formula: wherein R1, R3, R5, Q, Z, Y, V, X and X′ are as defined herein.
    Type: Grant
    Filed: March 13, 1997
    Date of Patent: December 4, 2001
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Robert John Chorvat, Parthasarathi Rajagopalan
  • Patent number: 6319912
    Abstract: This invention relates to cyclic combination therapies utilizing, in combination with a progestin, an estrogen, or both, progesterone receptor antagonists of the general structure: wherein the substituents are as defined herein, or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 19, 2000
    Date of Patent: November 20, 2001
    Assignees: American Home Products Corporation, Ligand Pharmaceuticals, Inc.
    Inventors: Gary S. Grubb, Lin Zhi, Todd K. Jones, James P. Edwards, Christopher M. Tegley, Mark A. Collins, Valerie A. Mackner, Jay E. Wrobel
  • Patent number: 6313111
    Abstract: Substitued 6H-1,3,4-thiadiazin-2-amines of the following general formula: wherein Ar is phenyl optionally substituted with one or more chloro, bromo atoms, C1-C4 alkoxy, or C1-C4 alkyl groups; and represents a morpholino, thimomorpholino, piperidino, pyrrolidino, or hexamethylenimino moieties, the pharmaceutically acceptable salts thereof and the use of them anasethetic, cardiovascular and hypometabolic agents and pharmaceutical compositions containing them.
    Type: Grant
    Filed: December 8, 1998
    Date of Patent: November 6, 2001
    Assignees: The Procter & Gamble Company, Nauchno-Tekhnologicheskoe Predpriyatie “Ligand” (Tovarischestvo S Ogranichennoi Otvetstvennostiju)
    Inventors: Oleg Nikolaevich Chupakhin, Larisa Petrovna Sidorova, Emma Afanasievna Tarakhty, Antonina Petrovna Novikova, Natalya Mikhailovna Perova, Valentin Antonovich Vinogradov, Michiel Franciscus van Ginkel
  • Patent number: 6303596
    Abstract: The invention relates to selective induction of cell death by apoptosis and applicability to treatment of leukemias.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: October 16, 2001
    Assignee: Oklahoma Medical Research Foundation
    Inventors: James H. Morrissey, Anne Hamik
  • Patent number: 6291516
    Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting a cell with a compound, such as a polypeptide or small molecule in an amount sufficient to control the aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity. The present invention further makes available methods and reagents for ameliorating the consequences of hedgehog loss-of-function, ptc gain-of-function, or smoothened loss-of-function comprising contacting a cell with a compound, such as a polypeptide or small molecule, in an amount sufficient to ameliorate the In certain embodiments, the subject compounds, e.g., a cAMP analog, adenylate cyclase agonist, or cAMP phosphodiesterase inhibitor, regulate cAMP levels, which in turn modulates activity of the hedgehog pathway.
    Type: Grant
    Filed: October 14, 1999
    Date of Patent: September 18, 2001
    Assignee: Curis, Inc.
    Inventors: Henryk Dudek, Benxiu Ji
  • Patent number: 6271235
    Abstract: HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 7, 2001
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Bruce A. Dressman, James E. Fritz, Stephen W. Kaldor, Vincent J. Kalish, Siegfried Heinz Reich, Michael J. Rodriguez, Timothy A. Shepherd, John H. Tatlock, Louis Nickolaus Jungheim
  • Publication number: 20010009911
    Abstract: Compound of formula (I): 1
    Type: Application
    Filed: December 29, 2000
    Publication date: July 26, 2001
    Inventors: Jean-Louis Peglion, Christophe Poitevin, Jean-Paul Vilaine, Nicole Villeneuve, Marie-Pierre Bourguignon, Catherine Thollon
  • Patent number: 6265398
    Abstract: The present invention relates to novel substituted pyridines/pyrimidines of the formula I where A is CH or N; X is NH, O or S(O)q where q is 0, 1 or 2; Y1, Y2 and Y3 independently of one another are a group of the formula —O—, —CO—, —CNR6—, —S(O)r— or —N(O)lR6— where l is 0 or 1 and where r is 0, 1 or 2, or a group of the formula CR7R8, or Y1 or Y3 replace a direct bond; Z is a direct bond, NR9, O, S(O)s where s is 0, 1 or 2, OSO2, SO2O, NR10SO2, SO2NR11, SiR12R13 or  where U is a direct bond, NR14 or O; W is oxygen or sulfur; V is a direct bond, NR15 or oxygen; m and n and 0, 1, 2, 3 or 4; where the radicals R1 to R15 have the meaning given in the description, to processes for their preparation, to their use as pesticides, fungicides and ovicides and to their use as veterinary medicaments.
    Type: Grant
    Filed: October 23, 1998
    Date of Patent: July 24, 2001
    Assignee: Hoechst Schering AgrEvo GmbH
    Inventors: Ralf Braun, Wolfgang Schaper, Herbert Stark, Rainer Preuss, Werner Knauf, Ulrich Sanft, Manfred Kern, Werner Bonin
  • Patent number: 6258797
    Abstract: The use of taurolidine or taurultam in a method of combatting infection or sepsis in delivery systems is disclosed. In the method, taurolidine or taurultam solutions are used as a temporary seal or flush to prevent or reduce sepsis in delivery systems, such as port systems and/or catheters by which liquids are delivered into a patient.
    Type: Grant
    Filed: June 21, 1999
    Date of Patent: July 10, 2001
    Assignee: Ed. Geistlich Soehne AG fuer Chemische Industrie
    Inventor: Joachim Hermann Lehner
  • Patent number: 6255303
    Abstract: The compounds of formula (I) in which R1, R2, R3, R4, R5, X and Y have the meanings as given in the description are novel effective bronchial therapeutica.
    Type: Grant
    Filed: September 13, 2000
    Date of Patent: July 3, 2001
    Assignee: Byk Gulden Lomberg Chemische Fabrik GmbH
    Inventors: Geert Jan Sterk, Margaretha van der Mey
  • Patent number: 6251896
    Abstract: The present invention relates to a method of treating a human infected with Crohn's disease comprising enterally administering to the individual in need of such treatment an effective amount of a composition comprising 4,4′-methylenebis-(tetrahydro-1,2,4-thiadiazine)-1,1,1′,1′-tetraoxide, commonly known as taurolidine.
    Type: Grant
    Filed: March 24, 2000
    Date of Patent: June 26, 2001
    Assignee: Carter-Wallace, Inc.
    Inventor: James C. Costin
  • Publication number: 20010003746
    Abstract: The present invention relates to a method of inhibiting or preventing infection and blood coagulation in or near a medical prosthetic device after said device has been inserted in a patient comprising administering to the device a pharmaceutically effective amount of a composition comprising:
    Type: Application
    Filed: December 20, 2000
    Publication date: June 14, 2001
    Inventor: Klaus Sodemann